The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Pulmonary artery denervation – the time has come for a multicentre blinded randomised controlled trial

EuroIntervention 2019;15:659-661. DOI: 10.4244/EIJV15I8A122



Pulmonary hypertension (PH) describes an abnormal pressure elevation in the lesser circulation that accompanies ageing, as well as cardiovascular and pulmonary disease, and many other systemic diseases. Pulmonary arterial hypertension (PAH) is a subset of PH that results from pulmonary vascular disease, an obliterative disorder that affects the precapillary <200 µm diameter arteriolar vessels, the capillary bed, and the small post-capillary venules. The mechanisms responsible for vasculopathy in PAH are poorly understood but probably involve vasoconstriction, altered vascular growth and proliferation, and potentially a central nervous system regulatory axis1,2,3. In support of this concept, experimental PH by distention ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Comparison of cardiac computed tomography angiography and transoesophageal echocardiography for device surveillance after left atrial appendage closure